IDEAYA BiosciencesIDYA
Recorded

IDEAYA Biosciences Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the IDEAYA management team. We've got Yujiro Hata, the CEO, and Josh Bleharski, the CFO. Thanks so much for joining us today.

Yujiro HataCEO

Thank you so much, Maury, and look forward to the discussion today.

Operator

We'll do fireside chat format. So maybe for those who are new to the story, if you can give a one-minute intro to the company.

Yujiro HataCEO

IDEAYA Biosciences, we're a leading precision medicine oncology company. Our lead program, darovasertib, recently had positive top-line results, which we presented at an oral presentation at ASCO. We did recently announce that at the end of the third quarter, we did complete the NDA submission. So we do anticipate having NDA acceptance on that here relatively soon. As you know, Maury, most of our analysts are projecting a first half of next year commercial launch in the metastatic uveal melanoma setting. In addition, we have a phase III adjuvant study that's now well underway. In addition, we have a very broad portfolio on DLL3-TOPO ADC. We did have an announcement this morning of our plans to also advance not just in small cell lung cancer, but also neuroendocrine carcinoma into a phase III study, as well as a potential single-arm design in GEP-NEC for potential accelerated approval.

Yujiro HataCEO

Beyond that, Maury, you were there at our R&D Day yesterday. We had a lot of key updates across the MTAP and CDKN2A pipeline. I would say big focus here is what we believe is a potential first-in-class molecule for PRMT5. We showed some early safety data, some pharmacodynamic data, as well as what we believe is a very clean drug-drug interaction profile to enable combinations with molecules such as pan-RAS and KRAS G12D. Also, we did profile a new molecule, CDKN2A, that we are targeting to have in the clinic in the first half of next year. This is targeting a biomarker setting of CDKN2A deficiency, which we believe represents a very large percentage of pancreatic cancer, approximately 70%. Lastly is around KAT6/7, our first-in-class dual inhibitor. Here, a significant focus on breast cancer.

Yujiro HataCEO

Also here, we showed some early safety data, some pharmacodynamic data, as well as an early response in a fifth-line breast cancer patient. So, a lot of activities and obviously a lot of upcoming catalysts in 2027 as well.

Operator

Yeah. I think that's a great intro. You have the upcoming commercial launch and approval, and then so much happening in the pipeline. So maybe let's dive into darovasertib first. You completed the NDA submission in third quarter under RTOR with Fast Track designation in place. How are you setting expectations for timing of the NDA acceptance announcement, and how should we think about the review timeline heading into 2027?

Yujiro HataCEO

Yeah. So we have a lot of different designations for this agent, including Fast Track, breakthrough, RTOR, orphan drug. The timing with the NDA submission at the end of the third quarter, we do think the NDA acceptance timing is here very soon. We have not provided specificity on that, Maury, but it will be anticipated this quarter. Then in terms of the review cycle or the review time period, because we have Fast Track designation as well as under RTOR, we do believe we will have an expedited review. So we have not specified exactly when. We anticipate we will likely do that once we have more visibility into the actual PDUFA date.

Operator

Got it. Okay. You described a positive trend in early OS with just over 10 months at ASCO from your dataset. How much extra follow-up is in the NDA, what proportion of OS events are in the filing? If the OS trend is positive, has FDA indicated to date whether they would be willing to include those data in the label?

Yujiro HataCEO

Yeah. The interim analysis for OS is projected for first half, sorry, middle of next year. We do anticipate it is going to still be early as it relates to the OS events. In terms of the question of how much more follow-up, there is roughly about six months more follow-up since what we provided at the top-line results. In terms of how many events that would represent from a percentage basis, I do not think we are prepared to make comments on that at this point yet. Would it be able to be incorporated into that approval? I think some of it will just depend on where we are on the events. As I mentioned earlier, I think we do think it is going to be likely early at this point.

Operator

Got it. Okay. There is debate on the HLA-positive population. At ESMO, you presented ORR and durability data from 11 treatment-naive and 75 previously treated HLA-positive patients with a March cutoff. The recent publication included a similarly sized frontline HLA-positive cohort with less follow-up. What gives you confidence that the dataset that you have is going to be sufficient for inclusion in the label or NCCN listing?

Yujiro HataCEO

Yeah. First, what we would start with is based on the mechanism of action. We know that our molecule is directly focused on the activating mutation of GNAQ/11, which is the predominance of this population, and that mechanism of action is not specifically linked to HLA-A2 status. I think that is really the first place to start. Second is the data that we presented at ESMO, roughly 100 patients in the HLA-A2 positive setting. Our perspective is the molecule is clearly active in that setting. That is the mindset by which we went through the process and filing the NDA. We also appreciate on this specific point, this will be ultimately a review issue with the FDA.

Yujiro HataCEO

This study was done in the HLA-A2 negative setting, but for all the reasons we noted, we are pursuing a broader approach, because we believe this therapy should be active across all metastatic uveal melanoma patients. Beyond that, either way, we will be also pursuing an NCCN strategy to be able to hopefully have this treatment available to patients more broadly.

Operator

Got it. Based on the events, and going back to OS, based on the events that you are seeing, sounds like you are pretty confident it is going to be middle of next year. Could that get bumped to second half? I guess, early next year, could you provide more granularity on timing around it?

Yujiro HataCEO

Yeah. We are going to have an assessment as part of the NDA submission. Again, it is not going to be a formal analysis because the interim, as noted, is middle of next year. Might we give some communication on that early next year? It is possible, but if we do not, I would not look into that either way. But yeah, at this point, we do not have a reprojection on that interim analysis from what we had noted earlier.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day